Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase  3 Trials in Adults with Mild to Severe Plaque Psoriasis

ConclusionTapinarof was highly efficacious in reducing pruritus across multiple patient-reported outcome measures, with rapid, statistically significant, and clinically meaningful improvements. The high proportion of patients achieving the treatment target of an itch-free state at week  12 (50%) is a noteworthy clinical outcome for a non-steroidal topical cream in the treatment of mild to severe plaque psoriasis.Trial RegistrationClinical trial registration information: NCT03956355, NCT03983980.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research